Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases... Show more
VERU is expected to report earnings to fall 13.33% to -25 cents per share on November 26
Q3'26
Est.
$-0.26
Q2'26
Beat
by $0.01
Q1'26
Missed
by $0.07
Q4'25
Missed
by $0.20
Q3'25
Beat
by $0.15
The last earnings report on August 10 showed earnings per share of -30 cents, beating the estimate of -31 cents. With 47.07K shares outstanding, the current market capitalization sits at 39.22M.